Evidence map›Paper›PMID 33107827›Full record

ArticleJMIR mHealth and uHealth2020

Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study.

Abhishek Pratap, Daniel Grant, Ashok Vegesna, Meghasyam Tummalacherla, Stanley Cohan, Chinmay Deshpande, Lara Mangravite, Larsson Omberg

Open access · goldAbstract read
In one paragraph

Article in JMIR mHealth and uHealth, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Smartphone-Based Hand Function Assessment: Systematic Review.Journal of medical Internet research · 2024
    Pooled it
  2. Pooled it
  3. Trial
  4. Preventive strategies in neuroimmunology.Neurological research and practice · 2026
    Review
  5. Observational
  6. A comprehensive guide to digital neurology. An update on current development on digital neurology derived from the Digital Neuro Hub project.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  7. Sensors in Multiple Sclerosis.Current neurology and neuroscience reports · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Digital Neuropsychology beyond Computerized Cognitive Assessment: Applications of Novel Digital Technologies.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Abhishek PratapSage Bionetworks, Seattle, WA, United States.ORCID 0000-0002-5289-6932
Daniel GrantNovartis Pharmaceuticals Corporation, East Hanover, NJ, United States.ORCID 0000-0002-5075-0091
Ashok VegesnaNovartis Pharmaceuticals Corporation, East Hanover, NJ, United States.ORCID 0000-0001-7531-5291
Meghasyam TummalacherlaSage Bionetworks, Seattle, WA, United States.ORCID 0000-0002-0741-8683
Stanley CohanProvidence Multiple Sclerosis Center, Providence St Vincent Medical Center, Portland, OR, United States.ORCID 0000-0002-9568-346X
Chinmay DeshpandeNovartis Pharmaceuticals Corporation, East Hanover, NJ, United States.ORCID 0000-0002-3682-0989
Lara MangraviteSage Bionetworks, Seattle, WA, United States.ORCID 0000-0001-7841-3612
Larsson Omberg *Sage Bionetworks, Seattle, WA, United States.ORCID 0000-0002-4719-9120
Sage Bionetworks · USNovartis (United States) · USProvidence St. Vincent Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS) is a chronic neurodegenerative disease. Current monitoring practices predominantly rely on brief and infrequent assessments, which may not be representative of the real-world patient experience. Smartphone technology provides an opportunity to assess people's daily-lived experience of MS on a frequent, regular basis outside of episodic clinical evaluations.

objectiveThe objectives of this study were to evaluate the feasibility and utility of capturing real-world MS-related health data remotely using a smartphone app, "elevateMS," to investigate the associations between self-reported MS severity and sensor-based active functional tests measurements, and the impact of local weather conditions on disease burden.

methodsThis was a 12-week, observational, digital health study involving 3 cohorts: self-referred participants who reported an MS diagnosis, clinic-referred participants with neurologist-confirmed MS, and participants without MS (controls). Participants downloaded the elevateMS app and completed baseline assessments, including self-reported physical ability (Patient-Determined Disease Steps [PDDS]), as well as longitudinal assessments of quality of life (Quality of Life in Neurological Disorders [Neuro-QoL] Cognitive, Upper Extremity, and Lower Extremity Function) and daily health (MS symptoms, triggers, health, mobility, pain). Participants also completed functional tests (finger-tapping, walk and balance, voice-based Digit Symbol Substitution Test [DSST], and finger-to-nose) as an independent assessment of MS-related cognition and motor activity. Local weather data were collected each time participants completed an active task. Associations between self-reported baseline/longitudinal assessments, functional tests, and weather were evaluated using linear (for cross-sectional data) and mixed-effects (for longitudinal data) regression models.

resultsA total of 660 individuals enrolled in the study; 31 withdrew, 495 had MS (n=359 self-referred, n=136 clinic-referred), and 134 were controls. Participation was highest in clinic-referred versus self-referred participants (median retention: 25.5 vs 7.0 days). The top 5 most common MS symptoms, reported at least once by participants with MS, were fatigue (310/495, 62.6%), weakness (222/495, 44.8%), memory/attention issues (209/495, 42.2%), and difficulty walking (205/495, 41.4%), and the most common triggers were high ambient temperature (259/495, 52.3%), stress (250/495, 50.5%), and late bedtime (221/495, 44.6%). Baseline PDDS was significantly associated with functional test performance in participants with MS (mixed model-based estimate of most significant feature across functional tests [β]: finger-tapping: β=-43.64, P<.001; DSST: β=-5.47, P=.005; walk and balance: β=-.39, P=.001; finger-to-nose: β=.01, P=.01). Longitudinal Neuro-QoL scores were also significantly associated with functional tests (finger-tapping with Upper Extremity Function: β=.40, P<.001; walk and balance with Lower Extremity Function: β=-99.18, P=.02; DSST with Cognitive Function: β=1.60, P=.03). Finally, local temperature was significantly associated with participants' test performance (finger-tapping: β=-.14, P<.001; DSST: β=-.06, P=.009; finger-to-nose: β=-53.88, P<.001).

conclusionsThe elevateMS study app captured the real-world experience of MS, characterized some MS symptoms, and assessed the impact of environmental factors on symptom severity. Our study provides further evidence that supports smartphone app use to monitor MS with both active assessments and patient-reported measures of disease burden. App-based tracking may provide unique and timely real-world data for clinicians and patients, resulting in improved disease insights and management.

Indexed as

Mobile ApplicationsMultiple SclerosisNeurodegenerative DiseasesCross-Sectional StudiesHumansProspective StudiesQuality of LifeSmartphonedigital healthmobile phonemultiple sclerosisneurodegenerationreal-world datareal-world evidenceremote monitoringsmartphone

Identifiers

PMID33107827
PMCPMC7655470
OpenAlexW3093779021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.